Apr 12 |
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
|
Apr 12 |
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company
|
Mar 27 |
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 17 |
Survey finds GLP-1 users more inclined to get aesthetic procedures
|
Mar 11 |
Revance stock rises after CEO discloses share purchase
|
Mar 11 |
GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session
|
Mar 4 |
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
|
Mar 4 |
Revance Therapeutics down 7%, prices $100M share offering
|
Mar 4 |
Revance Announces Proposed Public Offering of Common Stock
|
Mar 2 |
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript
|